SFI Health™ Reports Promising Results From a Preliminary Study Evaluating the Impact of Long-Chain Polyunsaturated Fatty Acids on Reading and Writing Skills in Children
27.11.2025 08:15:00 CET | Business Wire | Press Release
SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, is proud to announce the publication on Biomedicine of the results of a new study, conducted by the Italian research institute “IRCCS Eugenio Medea” of “La Nostra Famiglia” association, investigating the correlation between long-chain polyunsaturated fatty acids (LCPUFA) and reading and writing abilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126097656/en/
Italian Research Institute "IRCCS Eugenio Medea" of "La Nostra Famiglia".
This investigator-initiated trial is part of an ongoing project investigating the efficacy of omega-3 and omega-6 LCPUFA supplementation to enhance the effects of neuropsychological treatment in children diagnosed with developmental dyslexia (DD).
LCPUFAs of the omega-3 group, such as EPA and DHA, play essential roles in microglial activity, neuroinflammatory regulation, and synaptic plasticity—processes crucial for brain health and learning. Previous research has shown that individuals with dyslexia tend to have lower levels of these fatty acids in their blood, and this deficiency has been associated with slower and less accurate reading and writing performance.
The new study set out to determine which neurocognitive systems mediate the relationship between omega-3 LCPUFA levels and literacy skills in school-age children.
Seventy-four children with reading and writing skills ranging from normal to below average (DD) took part in an extensive neuropsychological assessment. Tasks evaluated reading and writing, auditory and visual processing (including measures related to magnocellular function), phonological awareness, attention, and executive functioning.
Researchers extracted three key neuropsychological factors—Auditory Phonological (AP), Visual-Perceptual (VP), and Visual-Attentional (VA) processing—and tested their mediating role between omega-3 LCPUFA levels and literacy performance using Generalized Linear Model mediation analyses. Interactions with other polyunsaturated fatty acids (PUFAs) were also examined.
The study found that omega-3 LCPUFA levels, especially EPA and DHA, were significantly correlated with children’s reading and writing abilities as well as with the three identified cognitive factors.
- Auditory-phonological processing emerged as a significant mediator of the effects of PUFAs—particularly EPA—on literacy performance.
- DHA and the AA/ALA ratio (the balance between arachidonic acid and alpha-linolenic acid) significantly affected the strength and direction of some of these relationships.
Dr. Maria Luisa Lorusso, Child Neuropsychologist and senior Researcher in the Department of Child Psychopathology at Scientific Institute IRCSS E. Medea, and responsible for the study, commented: “We are very excited to share these findings which provide new insight into how omega-3 fatty acids influence reading and writing development through their action on specific neurocognitive processes, particularly auditory-phonological mechanisms. We are grateful to SFI Health™ for their support along this study which underlines also the importance of the balance between different PUFAs in determining the overall cognitive benefits.”
Matthew Brabazon, General Manager at SFI Health™ EMEA, added: ”As a company that views research as a fundamental pillar of its mission to offer science-based natural healthcare products, we are extremely proud of this achievement. SFI Health™ has a long-standing tradition of strategic partnerships with leading universities and researchers around the world, all with the shared goal of combining expertise and capabilities to unlock the potential of natural-source ingredients for human health.”
While more research is needed to confirm whether increasing omega-3 intake can directly improve reading and writing skills, this study provides a valuable foundation for future work on the connections between diet, brain function, and learning.
Link to the publication: https://www.mdpi.com/2227-9059/13/10/2517#.
About SFI Health
SFI Health™ is a global leader in natural healthcare, specialized in the design, development and commercialization of clinically researched products in the areas of microbiome, cognition and wellbeing.
Guided by the belief in the healing potential of natural products, SFI Health™combines a rigorous pharma-based approach with the benefits of naturally sourced solutions.
An extensive network of trusted business partners enables the company, headquartered in Australia, to market its own brands, reaching consumers in over 50 countries. The EMEA SFI Health™ regional office in Lugano, Switzerland, manages commercial operations across Europe, Middle East and Africa.
SFI Health™ is committed to fostering confidence in natural healthcare by sharing state-of-the-art research, technical expertise and comprehensive sales & marketing resources with consumers, healthcare professionals and partners worldwide.
For more information go to sfihealth.com or follow us SFI Health on LinkedIn.
About IRCCS Medea of La Nostra Famiglia
Since 1985, the Scientific Institute IRCCS Eugenio Medea – La Nostra Famiglia has been committed to research, care, and rehabilitation in the field of neurological and neuropsychiatric disorders affecting children and adolescents. It operates in Bosisio Parini (Lecco), Conegliano (Treviso), and Pasian di Prato (Udine).
The Institute’s mission is to build strong connections between scientific research, clinical care, and technological innovation—always “on the side of children”—to safeguard their dignity and enhance the quality of life of its young patients.
For more info, please visit emedea.it or follow us on facebook - emedea.lanostrafamiglia, instagram - emedea_lanostrafamiglia, linkedin - associazione-la-nostra-famiglia
View source version on businesswire.com: https://www.businesswire.com/news/home/20251126097656/en/
Contacts
For more information
SFI Health™ EMEA Contact
Elisabetta Bianchi
e-mail address: elisabetta.bianchi@sfihealth.com
IRCCS Medea of La Nostra Famiglia Contact
e-mail address: ufficio.stampa@lanostrafamiglia.it
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom